These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 18814217)

  • 1. Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry.
    Lasala JM; Cox DA; Dobies D; Muhlestein JB; Katopodis JN; Revtyak G; Baim DS;
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):433-45. PubMed ID: 18814217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
    Lasala JM; Cox DA; Dobies D; Baran K; Bachinsky WB; Rogers EW; Breall JA; Lewis DH; Song A; Starzyk RM; Mascioli SR; Dawkins KD; Baim DS;
    Circ Cardiovasc Interv; 2009 Aug; 2(4):285-93. PubMed ID: 20031730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term paclitaxel-eluting stent outcomes in elderly patients.
    Forman DE; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Wei JY; Joshi AA; Dawkins KD; Baim DS
    Circ Cardiovasc Interv; 2009 Jun; 2(3):178-87. PubMed ID: 20031714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In-hospital complications and long-term outcomes of the paclitaxel drug-eluting stent in acute ST-elevation myocardial infarction: a real-world experience from a high-volume medical center.
    Shammas NW; Shammas GA; Hahn A; Jerin M; Dippel EJ; Winter M
    Cardiovasc Revasc Med; 2009; 10(3):151-5. PubMed ID: 19595395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One-year outcomes with the Taxus Liberté stent in the real world: the Taxus Olympia registry (phase I).
    Ahmed WH; Zambahari R; Al-Rashdan I; Al Naeemi A; Saeed FA; Mascioli S
    J Interv Cardiol; 2008 Dec; 21(6):512-8. PubMed ID: 18973513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents.
    Tamburino C; Angiolillo DJ; Capranzano P; Dimopoulos K; La Manna A; Barbagallo R; Tagliareni F; Mangiafico S; Guzman LA; Galassi AR; Bass TA
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):448-56. PubMed ID: 18814218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.
    Novack V; Tsyvine D; Cohen DJ; Pencina M; Dubin J; Dehghani H; Kleiman NS; Cutlip DE
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):874-80. PubMed ID: 19180665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
    Brilakis ES; Lasala JM; Cox DA; Berger PB; Bowman TS; Starzyk RM; Dawkins KD
    JACC Cardiovasc Interv; 2010 Jul; 3(7):742-50. PubMed ID: 20650436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel-eluting stents for the treatment of complex coronary lesions: immediate and 12-month results.
    Sheiban I; Ballari GP; Moretti C; Marra WG; Meliga E; Omedè P; Sciuto F; Trevi GP
    J Cardiovasc Med (Hagerstown); 2007 Aug; 8(8):582-8. PubMed ID: 17667028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term clinical outcomes of real-world experience using sirolimus-eluting stents in saphenous vein graft disease.
    Ramana RK; Ronan A; Cohoon K; Homan D; Sutherland J; Steen L; Liu J; Loeb H; Lewis BE
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):886-93. PubMed ID: 18412238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after percutaneous coronary intervention of ostial lesions in the era of drug-eluting stents.
    Freeman M; Clark DJ; Andrianopoulos N; Duffy SJ; Lim HS; Brennan A; Charter K; Shaw J; Horrigan M; Ajani AE; Sebastian M; Reid CM; Farouque HM;
    Catheter Cardiovasc Interv; 2009 May; 73(6):763-8. PubMed ID: 19309731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.
    Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS
    Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usage patterns and 1-year outcomes with the TAXUS Liberté stent: results of the TAXUS OLYMPIA registry.
    Ahmed WH; Mendiz OA; Thomas MR;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):979-92. PubMed ID: 20853350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAXUS VI 2-year follow-up: randomized comparison of polymer-based paclitaxel-eluting with bare metal stents for treatment of long, complex lesions.
    Grube E; Dawkins KD; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Buellesfeld L; Koglin J; Russell ME
    Eur Heart J; 2007 Nov; 28(21):2578-82. PubMed ID: 17938126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.
    Lasala JM; Cox DA; Morris DL; Breall JA; Mahoney PD; Horwitz PA; Shaw D; Hood KL; Mandinov L; Dawkins KD
    Am J Cardiol; 2009 Jun; 103(12):1663-71. PubMed ID: 19539073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
    Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label use and the spectre of drug-eluting stent thrombosis.
    Cook S; Wenaweser P
    Circ Cardiovasc Interv; 2009 Aug; 2(4):273-6. PubMed ID: 20031728
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
    Krucoff MW; Kereiakes DJ; Petersen JL; Mehran R; Hasselblad V; Lansky AJ; Fitzgerald PJ; Garg J; Turco MA; Simonton CA; Verheye S; Dubois CL; Gammon R; Batchelor WB; O'Shaughnessy CD; Hermiller JB; Schofer J; Buchbinder M; Wijns W;
    J Am Coll Cardiol; 2008 Apr; 51(16):1543-52. PubMed ID: 18420096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.